This suggests that hyperglycemia-induced upregulation of SHP-2 could have a critical role in monocyte dysfunction by promoting VEGF resistance to ultimately alter arteriogenesis in diabetic PAD patients. Here, PTPN11 is linked to peripheral arterial disease.